Policyholder Services


<< Back
Share
 Print

FDA Alert – Artificial Tears

On Feb. 3, the US Food and Drug Administration (FDA) issued a warning statement to consumers and health care practitioners to not purchase and to immediately stop using EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears, due to potential bacterial contamination. Both products have been voluntarily recalled.

The Centers for Disease Control (CDC) has developed related resources for health care providers:

The CDC continues to investigate the multistate outbreak of an extensively drug-resistant strain of Pseudomonas aeruginosa associated with artificial tears.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.

61864684